Navigation Links
OXIS International announces plans to Enter the Cannabis Biotech Sector, Completion of Financing, Changes to the Board of Directors
Date:8/10/2014

BEVERLY HILLS, Calif., Aug. 11, 2014 /PRNewswire/ -- Oxis International, Inc. (OXI.PA) announced today company management has changed the business and plans to enter the cannabis biotech space. To support the change of business, the company completed a $1.425 million financing. Mr. Anthony Cataldo has joined the OXIS Board of Directors and will serve as Chairman of the Board.

The changing landscape of medical marijuana laws sweeping the nation has created incredible opportunities for commercialization of cannabis related therapies. (OXI.PA) management team is currently in discussions to license certain intellectual property from some of the world's foremost authorities in the cannabis space. The just completed financing of $1.425 million will be used to bring the company's required SEC filings to current status, increase marketing of OXIS nutraceutical products, and investigate possible business acquisitions in the nutraceutical and/or marijuana sector.

As part of the change of business direction, directors Anshuman Dube and David Saloff have resigned from the Board of Directors. Mr. Anthony Cataldo has been appointed to the Board and will serve as Chairman. Mr. Cataldo has an extensive career in the biotech industry including most recently as Chairman and CEO of Genesis Biopharma , now Lion BIotechnologies Inc. (LBIO), where he was responsible for the acquisition of licenses and CRADA for various cancers utilizing T-cell therapy from the National Cancer Institute.

OXIS CEO Kenneth Eaton stated, "We are very excited about our new direction at OXIS. The cannabis industry provides our shareholders many opportunities that simply did not exist before. Our team at OXIS is uniquely positioned to take advantage of this new business sector."

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Oxis International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International Reports Fourth Quarter And Fiscal Year 2014 Results
2. Nerium International™ Expands to Mexico and Builds Executive Team, Top Skincare Company Announces Its Arrival in Mexico by October
3. The International Society for Cardiovascular Translational Research Announces the ISCTR 2014 Scholarship Awardee
4. International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio
5. Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting
6. Xybion Announces It Will Host International User Conference in Philadelphia
7. National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS
8. ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute
9. Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium
10. International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019
11. International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a ... promotion of two long-standing principal investigators (PI) to the roles of Chief Medical ... Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):